New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tivozanib hydrochloride monohydrate 1.5mg equivalent to 1340 microgram tivozanib - capsule - 1340 mcg - active: tivozanib hydrochloride monohydrate 1.5mg equivalent to 1340 microgram tivozanib excipient: gelatin   iron oxide yellow   magnesium stearate mannitol titanium dioxide   - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-na?ve following disease progression after one prior treatment with cytokine therapy for advanced rcc.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tivozanib hydrochloride monohydrate 1mg equivalent to 890 microgram tivozanib - capsule - 890 mcg - active: tivozanib hydrochloride monohydrate 1mg equivalent to 890 microgram tivozanib excipient: gelatin   indigo carmine iron oxide yellow magnesium stearate mannitol titanium dioxide   - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-na?ve following disease progression after one prior treatment with cytokine therapy for advanced rcc.

European Union - English - EMA (European Medicines Agency)

recordati netherlands b.v. - tivozanib - carcinoma, renal cell - antineoplastic agents - fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (rcc) and for adult patients who are vegfr and mtor pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced rcc. treatment of advanced renal cell carcinoma.,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eusa pharma ltd - tivozanib hydrochloride monohydrate - capsule - 1.34mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eusa pharma ltd - tivozanib hydrochloride monohydrate - capsule - .89mg

United States - English - NLM (National Library of Medicine)

aveo pharmaceuticals, inc. - tivozanib hydrochloride (unii: 8a9h4vk35z) (tivozanib - unii:172030934t) - fotivda is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (rcc) following two or more prior systemic therapies. none. risk summary based on findings in animal studies and its mechanism of action, fotivda can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data on fotivda use in pregnant woman to inform the drug-associated risk. in embryo-fetal developmental studies, oral administration of tivozanib to pregnant animals during the period of organogenesis caused maternal toxicity, fetal malformations and embryo-fetal death at doses below the maximum recommended clinical dose on a mg/m2 basis (see data) . advise pregnant woman of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the

Bangladesh - English - DGDA (Directorate General of Drug Administration)

everest pharmaceuticals ltd. - tivozanib hydrochloride - capsule - 1.5 mg

Canada - English - Health Canada

eisai limited - lenvatinib (lenvatinib mesylate) - capsule - 24mg - lenvatinib (lenvatinib mesylate) 24mg - antineoplastic agents

Canada - English - Health Canada

eisai limited - lenvatinib (lenvatinib mesylate) - capsule - 20mg - lenvatinib (lenvatinib mesylate) 20mg - antineoplastic agents

Canada - English - Health Canada

eisai limited - lenvatinib (lenvatinib mesylate) - capsule - 14mg - lenvatinib (lenvatinib mesylate) 14mg - antineoplastic agents